Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablet.
Published: 23 July 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Notification. Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and 40mg chewable tablets.
Further information, details of the affected batches and advice can be found on the MHRA website.